ClinicalTrials.gg
Drug

Mezigdomide clinical trials

Also written CC-92480 and BMS-986348.

studies test it
22
open now
10
in phase 3
2
first study started
2018

How each study uses mezigdomide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the mezigdomide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Mezigdomide
17
CELMoD CC-92480
2
Cereblon E3 Ligase Modulation Drug CC-92480
2
Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480
2
Cereblon Modulator CC-92480
2

Development codes

CC-92480
16
BMS-986348
11

Studies by the year they started

22 studies that test it; most in 2023 (5)

Studies that test mezigdomide, by start year
YearStudies
20182
20191
20201
20211
20222
20235
20243
20254
20263

By phase

A phase 1/2 study counts in both.

Phase 1
18
Phase 2
7
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 10

Celgene (8) · Bristol-Myers Squibb (3) · Memorial Sloan Kettering Cancer Center (2) · Massachusetts General Hospital (2) · City of Hope Medical Center (1) · Abdullah Khan (1) · PETHEMA Foundation (1) · K36 Therapeutics, Inc. (1)

Often tested with

Tested in the same studies.

Dexamethasone (3) · Elranatamab (2) · Carfilzomib (2) · Pomalidomide (1) · Gintemetostat (1) · Revumenib (1) · Teclistamab (1) · Ziftomenib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 7, 1 in phase 3

Studies that test mezigdomide, phase 3 first.

Studies

Open first, then newest update. How each study uses mezigdomide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 22

See all 22 studies that test mezigdomide →

Given beside what is tested · 6 — mezigdomide is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 17, 2026.

Codes

What other systems call mezigdomide · ClinicalTrials.gg INT017163

  • UNII (FDA) LA88IH4O02MEZIGDOMIDEConfirmed FDA, Wikidata
  • Wikidata Q123914054mezigdomideConfirmed FDA, Wikidata
  • NCI Thesaurus C146660MezigdomideOne source FDA
  • DrugBank DB17584One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.